BIND / BIND-M — Bilirubin-Induced Neurologic Dysfunction

BIND and its modified version BIND-M are bedside neurological scores designed to quantify early signs of acute bilirubin encephalopathy in jaundiced newborns. Each score uses three domains—mental status/feeding, tone/arching, and cry—rated 0 to 3, for a total of 0 to 9. Higher numbers indicate more concerning neurologic dysfunction. BIND-M refines the descriptors but preserves the same structure and scoring bands, so clinicians can use either variant consistently without changing the interpretation model.

Use the version endorsed by your institution or the one embedded in your local jaundice pathway. In this calculator, switching between BIND and BIND-M changes only the wording of the options; the math, thresholds, and summary text remain the same. The toggle also persists in the URL so a copied share link rehydrates the correct descriptors and selected choices.

The most common staging framework is 1–3 mild ABE (close monitoring and repeat exams), 4–6 moderate ABE (urgent evaluation and likely escalation), and 7–9 severe ABE (emergent care and higher-level support). A score of 0 indicates no neurologic signs attributable to bilirubin toxicity, but does not exclude risk if bilirubin levels are high or rising quickly.

1. Choose one variant (BIND or BIND-M) and keep that variant consistent for serial scoring.
2. Score all three domains with a timestamp and current bilirubin value context.
3. Compare with prior score and determine whether neurologic trajectory is stable, improving, or worsening.
4. Escalate immediately when score rises into moderate or severe range, or when red flags appear regardless of total.
5. Document next reassessment interval and responsible team.

BIND is intended for bedside assessment of neurologic signs in newborns with suspected hyperbilirubinemia. The evidence base is strongest in term and late-preterm infants; follow NICU-specific protocols for very preterm or medically complex infants.

• Confounders: sepsis, hypoglycemia, opioids/sedatives, hypoxic injury, or seizures can mimic ABE signs.
• Do not delay treatment when bilirubin exceeds thresholds; the score complements lab trends.
• Use serial scoring and document time stamps to track progression or response to therapy.

Mild scores (1–3) often capture early irritability or subtle tone changes. These infants still require close observation, repeat bilirubin checks, and low thresholds for escalation if risk factors are present (prematurity, hemolysis, sepsis, dehydration, low albumin). Document the trajectory across serial exams—stable mild findings with a falling TSB is reassuring, whereas a rising total or worsening neurologic signs should trigger immediate pathway review.

Moderate scores (4–6) suggest evolving neurotoxicity. Pair the score with a repeat TSB, rapid review of age-in-hours thresholds (AAP 2022), and a neonatology consult. Hypotonia, poor feeding, or high-pitched cry in this band typically warrants urgent treatment consideration, even before classic severe posturing appears. Many centers start phototherapy or escalate toward exchange transfusion decisions while simultaneously addressing hemolysis or dehydration.

Severe scores (7–9) reflect high concern for acute bilirubin encephalopathy with opisthotonus, stupor/coma, or a shrill cry. Treat these as emergencies: repeat or stat TSB, mobilize exchange transfusion resources, support airway/breathing/circulation, and call neonatology and transfusion services early. Document time stamps and responses to interventions to aid serial assessments and handoffs.

Escalate immediately when BIND findings accompany any of the following: rising or unknown TSB in a high-risk infant; poor feeding with lethargy; new or persistent retrocollis/opisthotonus; apnea, cyanosis, or abnormal vital signs; suspected sepsis or hemolysis; or any rapid change in cry or tone. The presence of more than one red flag should lower your threshold for exchange transfusion discussions.

• High-risk contexts: prematurity, G6PD deficiency, ABO/Rh incompatibility, sepsis, dehydration, cephalohematoma/bruise burden.
• Rapidly rising bilirubin or lack of expected decline on therapy.
• Clinical instability: apnea episodes, oxygen requirement, temperature instability, or abnormal perfusion.
• Parent reports of suddenly abnormal cry, poor arousability, or arching between feeds.

If any uncertainty remains about staging, repeat the exam with a second clinician and re-score together; clear documentation of serial scores helps justify escalation to phototherapy or exchange while demonstrating clinical due diligence.

• New lethargy, feeding decline, high-pitched cry, or worsening tone/arching.
• Rapid bilirubin rise or uncertainty about current bilirubin trend in a high-risk infant.
• Clinical instability (apnea, cyanosis, temperature instability, poor perfusion).
• Exam uncertainty or disagreement between raters on component severity.

• Variant used (BIND or BIND-M), current total, and component-level findings.
• Current bilirubin value with age-in-hours context and direction of change.
• Risk modifiers present (prematurity, hemolysis, sepsis, dehydration, low albumin).
• Therapies active or pending (phototherapy intensity, IVIG, exchange planning).
• Next reassessment time and explicit escalation trigger.

• Treating BIND as a replacement for bilirubin thresholds instead of a neurologic overlay.
• Failing to re-score after treatment changes, feeding decline, or tone/cry shifts.
• Documenting only the total score without component findings or exam context.
• Missing confounders (sepsis, hypoglycemia, sedatives) that can mimic bilirubin encephalopathy.
• Delaying escalation while waiting for repeat labs when neurologic trajectory is worsening.

BIND is a neurologic overlay on bilirubin management rather than a standalone decision tool. Always pair it with total serum bilirubin relative to age in hours (per AAP 2022 nomograms), risk modifiers, and local treatment bundles. For suspected hemolysis, obtain a direct antiglobulin test, hemoglobin/hematocrit, reticulocyte count, and consider G6PD screening. Ensure hydration, adequate calories, and temperature stability while definitive therapy is arranged.

Phototherapy should be initiated promptly when thresholds are crossed or if the infant is clinical high risk with moderate neurologic findings. Exchange transfusion planning should be started early for severe scores or rapid neurologic deterioration, even before confirmatory lab turnaround. Maintain normoglycemia, correct electrolytes, and monitor for apnea or seizures. Involve neonatology, transfusion medicine, and, when indicated, neurology or intensive care to coordinate care.

After improvement, continue close observation until neurologic signs and bilirubin levels stabilize. Provide a clear follow-up plan for bilirubin rechecks, feeding support, and early return precautions if tone or cry worsens. Document your BIND/BIND-M totals with timestamps so the next team can see the trajectory.

• Score total and component selections (mental status, tone/arching, cry).
• Postnatal age in hours and most recent TSB/TcB value with trend.
• Gestational age and neurotoxicity risk factors (hemolysis, sepsis, low albumin).
• Therapy initiated (phototherapy, IVIG, exchange preparation) and response timing.

Explain the score in plain language: which behaviors or tone changes are concerning, what the current band means, and what treatments you are starting or considering (phototherapy, possible exchange transfusion). Emphasize that the score tracks visible neurologic signs and does not replace bilirubin blood levels, so continued monitoring is essential even if the infant appears calmer after treatment begins.

Provide explicit return precautions: worsening feeding, high-pitched or inconsolable cry, arching or stiffening, decreased alertness, fever, or breathing difficulty. Encourage families to keep follow-up appointments for bilirubin checks and to report any sudden change in behavior. In the chart, pair each score with context (age in hours, TSB value/trend, risk factors, treatments initiated) to create a coherent clinical story across handoffs.

• BIND-M increased from 2 to 5 over 4 hours with worsening tone and feeding; high concern for evolving ABE.
• Most recent bilirubin is above treatment threshold for age in hours and risk profile; intensive phototherapy started.
• Neonatology and transfusion pathway activated; repeat serum bilirubin and neurologic exam scheduled in 2 hours.
• Parent counseling completed with clear escalation precautions and documented understanding.

• AAP 2022 Bilirubin calculator for age-in-hours phototherapy and exchange thresholds.
• Thompson HIE score when broader neonatal encephalopathy is a concern.
• CRIES pain scale to assess postoperative discomfort separately from neurologic injury.

• Johnson LH, Brown AK, Bhutani VK. Clinical trial of BIND scoring. Pediatrics. 1999.
• Radmacher PG et al. BMC Pediatr. 2015;15:28 — BIND-M validation.